Cover Image
市場調查報告書

Kite Pharma, Inc.的產品平台分析

Kite Pharma, Inc. - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 320919
出版日期 內容資訊 英文 44 Pages
訂單完成後即時交付
價格
Back to Top
Kite Pharma, Inc.的產品平台分析 Kite Pharma, Inc. - Product Pipeline Review - 2015
出版日期: 2015年12月23日 內容資訊: 英文 44 Pages
簡介

Kite Pharma, Inc.是總公司設立於美國的生物製藥企業,集中致力於修復患者的免疫系統、認識腫瘤、設計來被消滅的細胞工學處理之T細胞治療藥(eACT),癌症治療用新免疫醫藥品的藥物研發及開發。

本報告提供Kite Pharma, Inc.的治療藥開發平台現狀及各開發階段比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

目錄

Kite Pharma, Inc.的基本資料

  • Kite Pharma, Inc.概要
  • 主要資訊
  • 企業資料

Kite Pharma, Inc.:R&D概要

  • 主要的治療範圍

Kite Pharma, Inc.:開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品

Kite Pharma, Inc.:開發中產品概況

  • 臨床階段的開發中產品
    • 第二階段的產品/聯合治療模式
    • 第一階段的產品/聯合治療模式
  • 初期階段的開發中產品
    • 前臨床階段的產品/聯合治療模式

Kite Pharma, Inc.:藥物簡介

  • Cell Therapy to Inhibit NY ESO-1 for Cancer
  • Cell Therapy to Target EGFR vIII for Glioblastoma
  • KTE-C19 CAR
  • TCR-1
  • TCR-2
  • Cell Therapy to Inhibit SSX2 for Solid Tumor
  • TCR-3
  • TCR-4

Kite Pharma, Inc.:開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

Kite Pharma, Inc.:最新的開發平台資訊

Kite Pharma, Inc.:開發暫停中的計劃

Kite Pharma, Inc.:總公司和子公司的所在地

  • 總公司

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC07923CDB

Summary

Global Markets Direct's, 'Kite Pharma, Inc. - Product Pipeline Review - 2015', provides an overview of the Kite Pharma, Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Kite Pharma, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Kite Pharma, Inc. including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Kite Pharma, Inc.'s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Kite Pharma, Inc.'s pipeline products

Reasons to buy

  • Evaluate Kite Pharma, Inc.'s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Kite Pharma, Inc. in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Kite Pharma, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Kite Pharma, Inc. and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Kite Pharma, Inc.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Kite Pharma, Inc. and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Kite Pharma, Inc. Snapshot
    • Kite Pharma, Inc. Overview
    • Key Information
    • Key Facts
  • Kite Pharma, Inc. - Research and Development Overview
    • Key Therapeutic Areas
  • Kite Pharma, Inc. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • Kite Pharma, Inc. - Pipeline Products Glance
    • Kite Pharma, Inc. - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
  • Kite Pharma, Inc. - Early Stage Pipeline Products
    • Preclinical Products/Combination Treatment Modalities
  • Kite Pharma, Inc. - Unknown Stage Pipeline Products
    • Unknown Products/Combination Treatment Modalities
  • Kite Pharma, Inc. - Drug Profiles
    • Cellular Immunotherapy to Inhibit NY ESO-1 for Oncology
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • KTEC-19
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Cellular Immunotherapy to Target EGFR vIII for Glioblastoma, Brain Cancer, Head and neck cancer
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Cellular Immunotherapy to Target HPV-16 E6 Protein for Cancer
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Cellular Immunotherapy to Target MAGE A3 for Oncology
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Cellular Immunotherapy to Target MAGE A3 and A6 for Oncology
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Cellular Immunotherapy for Hematological Malignancies and Solid Tumors
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Cellular Immunotherapy to Target HPV-16 E7 Protein for Head and Neck Cancer and Cervical Cancer
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Cellular Immunotherapy to Target SSX2 for Solid Tumor
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Kite Pharma, Inc. - Pipeline Analysis
    • Kite Pharma, Inc. - Pipeline Products by Target
    • Kite Pharma, Inc. - Pipeline Products by Route of Administration
    • Kite Pharma, Inc. - Pipeline Products by Molecule Type
    • Kite Pharma, Inc. - Pipeline Products by Mechanism of Action
  • Kite Pharma, Inc. - Recent Pipeline Updates
  • Kite Pharma, Inc. - Dormant Projects
  • Kite Pharma, Inc. - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Kite Pharma, Inc., Key Information
  • Kite Pharma, Inc., Key Facts
  • Kite Pharma, Inc. - Pipeline by Indication, 2015
  • Kite Pharma, Inc. - Pipeline by Stage of Development, 2015
  • Kite Pharma, Inc. - Monotherapy Products in Pipeline, 2015
  • Kite Pharma, Inc. - Phase II, 2015
  • Kite Pharma, Inc. - Phase I, 2015
  • Kite Pharma, Inc. - Preclinical, 2015
  • Kite Pharma, Inc. - Unknown, 2015
  • Kite Pharma, Inc. - Pipeline by Target, 2015
  • Kite Pharma, Inc. - Pipeline by Route of Administration, 2015
  • Kite Pharma, Inc. - Pipeline by Molecule Type, 2015
  • Kite Pharma, Inc. - Pipeline Products by Mechanism of Action, 2015
  • Kite Pharma, Inc. - Recent Pipeline Updates, 2015
  • Kite Pharma, Inc. - Dormant Developmental Projects,2015
  • Kite Pharma, Inc., Subsidiaries

List of Figures

  • Kite Pharma, Inc. - Pipeline by Top 10 Indication, 2015
  • Kite Pharma, Inc. - Pipeline by Stage of Development, 2015
  • Kite Pharma, Inc. - Monotherapy Products in Pipeline, 2015
  • Kite Pharma, Inc. - Pipeline by Top 10 Target, 2015
  • Kite Pharma, Inc. - Pipeline by Top 10 Route of Administration, 2015
  • Kite Pharma, Inc. - Pipeline by Top 10 Molecule Type, 2015
  • Kite Pharma, Inc. - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top